Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Galecto, Inc. (GLTO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 SC 13G Otto Erik reports a 6.7% stake in Galecto, Inc.
10/02/2023 144 Form 144 - Report of proposed sale of securities:
10/02/2023 144 Form 144 - Report of proposed sale of securities:
10/02/2023 144 Form 144 - Report of proposed sale of securities:
10/02/2023 144 Form 144 - Report of proposed sale of securities:
10/02/2023 8-K Quarterly results
09/26/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "Galecto Announces Plans to Explore Strategic Alternatives"
08/21/2023 144/A Form 144/A - Report of proposed sale of securities: [Amend]
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/17/2023 SC 13D/A ORBIMED ADVISORS LLC reports a 5.9% stake in Galecto, Inc.
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis Announces next steps for clinical development plan in severe liver diseases Boston, MA, August 15, 2023 - Galecto, Inc. , a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments for fibrosis and cancer, today announced topline results from its Phase 2b GALACTIC-1 trial evaluating the safety and efficacy of inhaled GB0139 for the treatment of idiopathic pulmonary fibrosis . The GALACTIC-1 trial did not meet its primary endpoint of change from baseline in rate of decline in forced vital capacity . Based on the results of the GALACTIC-1 trial, Galecto plans to discontinue development of GB0139. Going f..."
08/02/2023 SC 13D/A ORBIMED ADVISORS LLC reports a 8.3% stake in Galecto, Inc.
07/31/2023 144 Form 144 - Report of proposed sale of securities:
07/31/2023 144 Form 144 - Report of proposed sale of securities:
07/31/2023 144 Form 144 - Report of proposed sale of securities:
07/31/2023 144 Form 144 - Report of proposed sale of securities:
07/31/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/25/2023 144 Form 144 - Report of proposed sale of securities:
07/25/2023 144 Form 144 - Report of proposed sale of securities:
07/25/2023 144 Form 144 - Report of proposed sale of securities:
07/25/2023 144 Form 144 - Report of proposed sale of securities:
07/17/2023 SC 13D/A ORBIMED ADVISORS LLC reports a 9.6% stake in Galecto, Inc.
07/13/2023 144 Form 144 - Report of proposed sale of securities:
07/13/2023 144 Form 144 - Report of proposed sale of securities:
07/13/2023 144 Form 144 - Report of proposed sale of securities:
07/13/2023 144 Form 144 - Report of proposed sale of securities:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy